Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)
Putri Indah Permatasari
Departement of Pharmacy STIKes Widya Dharma Husada Tangerang, Jl. Pajajaran No. 1 Pamulang, Kota Tangerang Selatan, Banten, Indonesia.
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
COVID-19 and Diabetes Mellitus at RSU South Tangerang-Indonesia: Clinical Profile and Treatment Strategies: COVID-19 dan Diabetes Mellitus di RSU Tangerang Selatan-Indonesia: Profil Klinis dan strategi pengobatan Nur Hasanah; Nurwulan Adi Ismaya; Silvester Maximus Tulandi; Putri Indah Permatasari; Wafa Wafa; Amelia Nurul Hakim
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 9 No. 2 (2023): (October 2023)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2023.v9.i2.15989

Abstract

Background: Diabetes Mellitus is one of the risk factors for COVID-19. This causes the morbidity and severity of COVID-19 patients to be higher in patients with diabetes. Objectivity: This study aimed to determine the effectiveness of treatment therapy for COVID-19 patients with comorbid diabetes at the South Tangerang City General Hospital. Material and methods: This study used a descriptive design with a quantitative approach and retrospective data collection. Sampling was done by Total Sampling with a total sample of 127 patients from 234 patients. Result: The characteristics of COVID-19 patients with comorbid diabetes were dominated by the male gender (55.1%), with an age range of 46-55 years (38.6%), high school education (43.3%), and have a private employee type of work (55.1%). The symptoms of COVID-19 patients with comorbid diabetes were cough (89.8%), with a length of stay for patients 7–14 days (72.4%).Treatment for COVID-19 with comorbid diabetes was antibiotics azithromycin (26.0%), antiviral remdesivir (62.2%), methylprednisolone (73.2%), acetylcysteine (85.0%), vitamin C (89.8%), and the antidiabetic group that is often used is insulin novorapid (41.7%). Conclusion: The results of laboratory examinations showed that COVID-19 treatment therapy is effective in reducing the amount of virus in the blood, which is indicated by an increase in the PCR value (p-value <0.001), lowering blood sugar levels (which is characterized by a decrease in blood sugar levels when (p-value <0.001) ), and reduce hypercoagulation which is characterized by a reduction in the value of D-dimer (p-value < 0.005).
Co-Authors Amelia Nurul Hakim Nur Hasanah Nurwulan Adi Ismaya Silvester Maximus Tulandi Wafa Wafa